Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ans.16328 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Morphology of the Soft Palate Tonsil Mucosa of Collared Peccary (Pecari tajacu, Linnaeus, 1758).
Anat Histol Embryol
January 2025
Laboratório de Morfologia e Atividade Física, São Paulo State University, Rio Claro, São Paulo, Brazil.
Collared Peccary (Pecari tajacu, Linnaeus, 1758) is a mammalian Tayassuidae species from tropical to semi-arid areas. The morphological features of the oral cavity in this species were identified and described. Tonsils are secondary lymphoid organs essential for contact with antigens due to food and air intake.
View Article and Find Full Text PDFRecurrent and Metastatic Head and Neck Cancer: Mechanisms of Treatment Failure, Treatment Paradigms, and New Horizons.
Cancers (Basel)
January 2025
Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 71103, USA.
Head and neck cancer is a deadly disease with over 500,000 cases annually worldwide. Metastatic head and neck cancer accounts for a large proportion of the mortality associated with this disease. Many advances have been made in our understanding of the mechanisms of metastasis.
View Article and Find Full Text PDFDynamic Changes in Circulating Tumor DNA During Immunotherapy for Head and Neck Cancer: SHIZUKU-HN Study.
Int J Mol Sci
December 2024
Department of Medical Oncology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo 113-8510, Japan.
Immune checkpoint inhibitors (ICIs) are effective in treating recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but only 20% of patients achieve durable responses. This study evaluated circulating tumor DNA (ctDNA) as a real-time biomarker for monitoring treatment response in HNSCC. The SHIZUKU-HN study prospectively collected and analyzed serial plasma samples (n = 27) from HNSCC patients undergoing ICIs, using Guardant360 to assess ctDNA variant allele frequency (VAF) and genetic mutations.
View Article and Find Full Text PDFA study protocol for individualized prognostic counselling in the palliative phase.
BMC Palliat Care
January 2025
Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Dr. Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.
Background: Head and neck squamous cell cancer (HNSCC) has a poor prognosis, with approximately 25-30% of patients transitioning into the palliative phase at some point. The length of this phase is relatively short, with a median duration of five months. Patients in this stage often have increased prognostic information needs.
View Article and Find Full Text PDFTreatment outcomes of primary salivary gland squamous cell carcinoma: A multi-institutional retrospective study in Japan.
Auris Nasus Larynx
January 2025
Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Objective: Primary salivary gland squamous cell carcinoma (SCC) is extremely rare, accounting for 0.3-10.4 % of all salivary gland malignancies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!